Rentschler Biopharma and Coriolis Pharma announce strategic collaboration for integrated biopharma solutions
Collaboration combines complementary scientific and technical expertise to provide seamless solutions along the entire biopharmaceutical value chain
Advertisement
Rentschler Biopharma SE and Coriolis Pharma announced that they have entered into a strategic collaboration.
Together, the companies will provide clients with seamless end-to-end solutions, from early formulation to commercial manufacturing, leveraging their complementary expertise to accelerate the path from product to market. This collaboration serves the evolving needs of the biopharma market, where the increasing complexity of modalities and regulatory requirements is driving demand for integrated, science-based solutions. Customers will benefit from a unified interface and aligned project teams, reducing technology transfer hurdles and enabling faster project progression from early development to clinical and commercial phases.
Coriolis Pharma brings a unique combination of in silico and wet lab formulation expertise, drug development expertise, scientific competence and state-of-the-art analytical methods to this collaboration. With scientific excellence and a clear focus on innovation, Coriolis supports every stage of drug development, from R&D to GMP. The company's collaborative approach and deep scientific expertise make it a proven partner - from development to commercial manufacturing and lifecycle management.
Rentschler Biopharma combines decades of experience in the development and manufacture of biotherapeutics with an impressive track record of reliability and outstanding quality. With a strong commitment to client-centered solutions, the company offers comprehensive services from process development to commercial supply. Through its focus on technical excellence, long-term partnerships and customized solutions, Rentschler Biopharma ensures successful outcomes at all project stages.
The integrated service offering will be available to clients from December 2025. Both companies have offices in Germany and the United States, offering clients both global reach and local access in key biopharmaceutical markets.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
Other news from the department business & finance
